Previous close | 0.6500 |
Open | 0.6500 |
Bid | 0.0000 |
Ask | 1.0500 |
Strike | 2.50 |
Expiry date | 2024-10-18 |
Day's range | 0.6500 - 0.6500 |
Contract range | N/A |
Volume | |
Open interest | 3 |
Lyell Immunopharma ( NASDAQ:LYEL ) First Quarter 2024 Results Key Financial Results Net loss: US$60.7m (loss narrowed...
Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T‑cell product candidate, this quarterOn track to report initial clinical data from the Phase 1 trial of LYL845, an epigenetically enhanced TIL product candidate, in the second half of 2024IND for second generation ROR1-targeted CAR T-cell product candidate on track for submission this quarterCash, cash equivalents and marketable securities of $526.3 million as of March 31, 2024 supports
Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over...